A previous study has reported the ability of Cu-B to inhibit B-RAF and MEK by binding to the hydrophobic pocket of B-RAF receptor and allosteric site of MEK via molecular docking studies and has indicated the anti-melanoma potential of Cu-B by targeting the MAPK pathway (13). Here, MAP2K7 is linked to melanoma.